Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
BEDMINSTER, N.J., July 18, 2016 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), based in Bedminster, NJ, focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the July 14 presentation from Randy Milby, Chief Executive Officer, is now available for on-demand viewing at VirtualInvestorConferences.com.
CorMedix Inc.'s presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Highlights
- Currently enrolling a Phase 3 trial of its lead product, Neutrolin®, which has received U.S. FDA Fast-track status
- Substantial value may be unlocked through taurolidine use in oncology indications and medical device applications
- Neutrolin currently CE Marked and available in EU and Middle East
- Post-market data demonstrated that use of Neutrolin is associated with 96.0% reduction in the rate of CRBSI and 96.7% reduction in thrombosis compared to published historical benchmarks
Learn more about the event at www.VirtualInvestorConferences.com.
CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated a Phase 3 clinical study of a novel anti-infective solution Neutrolin in hemodialysis patients in the United States in December 2015. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also has designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world. For more information visit: www.cormedix.com.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE CorMedix Inc.